Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from ...
Vera Therapeutics (VERA) announced data from the ORIGIN Phase 3 trial of atacicept in IgA nephropathy were presented as a featured late-breaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback